Weisberg, Alec D

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. [electronic resource] - Arteriosclerosis, thrombosis, and vascular biology Feb 2005 - 365-71 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

1524-4636

10.1161/01.ATV.0000152356.85791.52 doi


Acetates--pharmacology
Administration, Oral
Angiotensin II--toxicity
Animals
Antigens, Differentiation--biosynthesis
Aorta--drug effects
Aortic Diseases--chemically induced
Blood Pressure--drug effects
Chemokine CCL2--biosynthesis
Collagen Type I--biosynthesis
Collagen Type III--biosynthesis
Drug Evaluation, Preclinical
Fibronectins--biosynthesis
Fibrosis
Gene Expression Regulation--drug effects
Glomerulosclerosis, Focal Segmental--chemically induced
Heart--drug effects
Hypertrophy, Left Ventricular--chemically induced
Indoleacetic Acids
Indoles--pharmacology
Kidney--drug effects
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Myocardium--metabolism
Nephrectomy
Osteopontin
Plasminogen Activator Inhibitor 1--deficiency
RNA, Messenger--biosynthesis
Random Allocation
Sialoglycoproteins--biosynthesis
Single-Blind Method
Sodium Chloride, Dietary--toxicity